GlaxoSmithKline PLC ADR (GSK)vsHCA Holdings Inc (HCA)
GSK
GlaxoSmithKline PLC ADR
$54.71
+3.32%
HEALTHCARE · Cap: $104.12B
HCA
HCA Holdings Inc
$484.02
-0.35%
HEALTHCARE · Cap: $108.62B
Smart Verdict
WallStSmart Research — data-driven comparison
HCA Holdings Inc generates 131% more annual revenue ($75.60B vs $32.67B). GSK leads profitability with a 17.5% profit margin vs 9.0%. GSK appears more attractively valued with a PEG of 0.50. GSK earns a higher WallStSmart Score of 70/100 (B).
GSK
Strong Buy70
out of 100
Grade: B
HCA
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+66.0%
Fair Value
$172.22
Current Price
$54.71
$117.51 discount
Margin of Safety
+59.9%
Fair Value
$1326.31
Current Price
$484.02
$842.29 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 43 in profit
Earnings expanding 54.7% YoY
Large-cap with strong market position
Attractively priced relative to earnings
Generating 1.5B in free cash flow
Every $100 of equity generates 136 in profit
Conservative balance sheet, low leverage
Large-cap with strong market position
Attractively priced relative to earnings
Earnings expanding 44.5% YoY
Areas to Watch
Trading at 10.1x book value
Elevated debt levels
Distress zone — elevated risk
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, EPS Growth. Profitability is solid with margins at 17.5% and operating margin at 18.9%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : HCA
The strongest argument for HCA centers on Return on Equity, Debt/Equity, Market Cap. PEG of 1.35 suggests the stock is reasonably priced for its growth.
Bear Case : GSK
The primary concerns for GSK are Price/Book, Debt/Equity, Altman Z-Score.
Bear Case : HCA
The primary concerns for HCA are Altman Z-Score.
Key Dynamics to Monitor
GSK profiles as a mature stock while HCA is a value play — different risk/reward profiles.
HCA carries more volatility with a beta of 1.34 — expect wider price swings.
HCA is growing revenue faster at 6.7% — sustainability is the question.
GSK generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
GSK scores higher overall (70/100 vs 69/100), backed by strong 17.5% margins. HCA offers better value entry with a 59.9% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
HCA Holdings Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
HCA Healthcare is an American for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owns and operates 186 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 21 states and the United Kingdom.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?